Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 10/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23891672 | 0.90 | CCKBR (0.34) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22039456 | 0.88 | BACE1 (0.38) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL23891729 | 0.86 | EP300 (0.33) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22040146 | 0.83 | EP300 (0.47) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22040127 | 0.83 | EP300 (0.43) | NR1H2EP300CREBBPCYP3A4CYP2C8 | |
| SCHEMBL17605850 | 0.83 | EP300 (0.43) | NR1H2EP300CREBBPCYP3A4CYP2C8 | |
| SCHEMBL17605847 | 0.83 | EP300 (0.43) | NR1H2EP300CREBBPCYP3A4CYP2C8 | |
| SCHEMBL22039457 | 0.81 | PDGFRB (0.35) | EP300CREBBPCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL22040804 | 0.77 | NR1H2 (0.34) | NR1H2 | |
| SCHEMBL23891706 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3889138-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108500-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | 成都海创药业有限公司 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | NR1H2 1284/4885EP300 1/4885CREBBP 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.